Maker of blockbuster Wegovy and Ozempic treatments reports 21% rise in third-quarter sales

RTÉ

Ireland

Novo Nordisk narrows 2024 guidance range

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.

Ad Fontes Media

All Sides

Media Bias/Fact Check

CNBC

Roberts family

United States

Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance

Novo Nordisk has today reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.

Government of Ireland

Safety Concerns Surrounding Compounded Diabetes Drugs  Novo Nordisk has reported 100 hospitalizations and 10 deaths associated with compounded copies of its popular weight-loss and diabetes drugs, the company's Chief Financial Officer Karsten Munk Knudsen announced on Wednesday. The drugmaker has been evaluating numerous compounded products available in the market, uncovering serious safety concerns alongside these alarming reports.In response, …

Devdiscourse

Safety Concerns Surrounding Compounded Diabetes Drugs

Financial Times

Nikkei Inc.

London

Greater London

England

United Kingdom

Novo Nordisk maintains booming sales of obesity and diabetes drugs

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints. Novo Nordisk has a hold on 74 percent of the market...

Legit.ng - Nigeria news.

Ikeja

Lagos

Nigeria

Obesity drug maker Novo Nordisk posts strong profit - Nigeria News Update

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.

BizToc

Novo Nordisk Q3 in line with expectations, narrows FY guidance range

The company's third quarter performance largely met analysts forecasts, with Wegovy sales showing continued growth.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

Novo Nordisk reports continued growth in obesity drug sales

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints. Novo Nordisk has a hold on 74 percent of the market for weight-loss treatments.

Tuko.co.ke - Kenya news.

Obesity drug maker Novo Nordisk posts strong profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted on Wednesday (Nov 6) strong third-quarter earnings despite being held back by production constraints.

Novo Nordisk maintains booming sales of obesity and diabetes drugs

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics